{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:12:48Z","timestamp":1755216768279,"version":"3.43.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,4]]},"DOI":"10.7759\/cureus.89360","type":"journal-article","created":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T19:00:20Z","timestamp":1754334020000},"source":"Crossref","is-referenced-by-count":0,"title":["Effects of Dapagliflozin on Obese Patients With Type 2 Diabetes: A Prospective Observational Study From Bangladesh"],"prefix":"10.7759","author":[{"given":"Somya Binte","family":"Akhond","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamila","family":"Bupasha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gull E","family":"Jannat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lubna","family":"Sharmin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Md Nazmul Hossain","family":"Sumon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruma","family":"Akhter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fahim","family":"Mahbub","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2017.03.024","article-title":"IDF Diabetes Atlas: global estimates for the prevalence of diabetes for 2015 and 2040","volume":"128","author":"Ogurtsova K","year":"2017","unstructured":"Ogurtsova K, da Rocha Fernandes JD, Huang Y, et al.. IDF Diabetes Atlas: global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract. 2017, 128:40-50. 10.1016\/j.diabres.2017.03.024","journal-title":"Diabetes Res Clin Pract"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a009728","article-title":"Estimating prevalence of type 1 and type 2 diabetes in a population of African Americans with diabetes mellitus","volume":"149","author":"Boyle JP","year":"1999","unstructured":"Boyle JP, Engelgau MM, Thompson TJ, et al.. Estimating prevalence of type 1 and type 2 diabetes in a population of African Americans with diabetes mellitus. Am J Epidemiol. 1999, 149:55-63. 10.1093\/oxfordjournals.aje.a009728","journal-title":"Am J Epidemiol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2016.08.001","article-title":"Hypertension, obesity, diabetes, and\u00a0heart\u00a0failure-free survival: the cardiovascular disease lifetime risk pooling project","volume":"4","author":"Ahmad FS","year":"2016","unstructured":"Ahmad FS, Ning H, Rich JD, Yancy CW, Lloyd-Jones DM, Wilkins JT. Hypertension, obesity, diabetes, and\u00a0heart\u00a0failure-free survival: the cardiovascular disease lifetime risk pooling project. JACC Heart Fail. 2016, 4:911-9. 10.1016\/j.jchf.2016.08.001","journal-title":"JACC Heart Fail"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.576","article-title":"Physical activity advice only or structured exercise training and association with HbA1c levels in type 2 diabetes: a systematic review and meta-analysis","volume":"305","author":"Umpierre D","year":"2011","unstructured":"Umpierre D, Ribeiro PA, Kramer CK, et al.. Physical activity advice only or structured exercise training and association with HbA1c levels in type 2 diabetes: a systematic review and meta-analysis. JAMA. 2011, 305:1790-9. 10.1001\/jama.2011.576","journal-title":"JAMA"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.soard.2016.05.018","article-title":"Metabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by international diabetes organizations","volume":"12","author":"Rubino F","year":"2016","unstructured":"Rubino F, Nathan DM, Eckel RH, et al.. Metabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by international diabetes organizations. Surg Obes Relat Dis. 2016, 12:1144-62. 10.1016\/j.soard.2016.05.018","journal-title":"Surg Obes Relat Dis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-020-0392-2","article-title":"Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus","volume":"16","author":"Scheen AJ","year":"2020","unstructured":"Scheen AJ. Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2020, 16:556-77. 10.1038\/s41574-020-0392-2","journal-title":"Nat Rev Endocrinol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray JJ","year":"2019","unstructured":"McMurray JJ, Solomon SD, Inzucchi SE, et al.. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019, 381:1995-2008. 10.1056\/NEJMoa1911303","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink HJ","year":"2020","unstructured":"Heerspink HJ, Stef\u00e1nsson BV, Correa-Rotter R, et al.. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020, 383:1436-46. 10.1056\/NEJMoa2024816","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.7326\/M20-0289","article-title":"Sodium-glucose cotransporter-2 inhibitors and the risk for diabetic ketoacidosis: a multicenter cohort study","volume":"173","author":"Douros A","year":"2020","unstructured":"Douros A, Lix LM, Fralick M, et al.. Sodium-glucose cotransporter-2 inhibitors and the risk for diabetic ketoacidosis: a multicenter cohort study. Ann Intern Med. 2020, 173:417-25. 10.7326\/M20-0289","journal-title":"Ann Intern Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-1884","article-title":"SGLT2 inhibitors may predispose to ketoacidosis","volume":"100","author":"Taylor SI","year":"2015","unstructured":"Taylor SI, Blau JE, Rother KI. SGLT2 inhibitors may predispose to ketoacidosis. J Clin Endocrinol Metab. 2015, 100:2849-52. 10.1210\/jc.2015-1884","journal-title":"J Clin Endocrinol Metab"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2012.697053","article-title":"Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor","volume":"28","author":"Nyirjesy P","year":"2012","unstructured":"Nyirjesy P, Zhao Y, Ways K, Usiskin K. Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor. Curr Med Res Opin. 2012, 28:1173-8. 10.1185\/03007995.2012.697053","journal-title":"Curr Med Res Opin"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2337\/dc23-Sint","article-title":"Introduction and methodology: Standards of Care in Diabetes-2023","volume":"46","author":"ElSayed NA","year":"2023","unstructured":"ElSayed NA, Aleppo G, Aroda VR, et al.. Introduction and methodology: Standards of Care in Diabetes-2023. Diabetes Care. 2023, 46:S1-4. 10.2337\/dc23-Sint","journal-title":"Diabetes Care"},{"key":"ref13","unstructured":"Obesity . preventing and managing the global epidemic : report of a WHO consultation. (2000). Accessed: April 2, 2025: https:\/\/iris.who.int\/handle\/10665\/42330."},{"key":"ref14","unstructured":"Guideline for quality assurance of locally sourced medical products for public health priority disease. (2024). Accessed. April 2, 2025: https:\/\/dgda.portal.gov.bd\/sites\/default\/files\/files\/dgda.portal.gov.bd\/policies\/0f8aa3d5_7b80_4528_8391_f2229dc4ffc2...."},{"key":"ref15","unstructured":"European Association for the Study of Diabetes (EASD). Statements & guidelines. Accessed. April 2, 2025: https:\/\/www.easd.org\/guidelines\/statements-guidelines\/."},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.87090","article-title":"Prevalence and associated factors of prediabetes and diabetes in rural and peri-urban Bangladesh: a community-based cross-sectional study","volume":"17","author":"Sujon H","year":"2025","unstructured":"Sujon H, Rahman MM, Haque MA, Banu S, Ananta TT, Sarker MH. Prevalence and associated factors of prediabetes and diabetes in rural and peri-urban Bangladesh: a community-based cross-sectional study. Cureus. 2025, 17:e87090. 10.7759\/cureus.87090","journal-title":"Cureus"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(18)30204-3","article-title":"Epidemiology and determinants of type 2 diabetes in south Asia","volume":"6","author":"Hills AP","year":"2018","unstructured":"Hills AP, Arena R, Khunti K, et al.. Epidemiology and determinants of type 2 diabetes in south Asia. Lancet Diabetes Endocrinol. 2018, 6:966-78. 10.1016\/S2213-8587(18)30204-3","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.deman.2021.100037","article-title":"Prevalence and associated factors of metabolic syndrome among Bangladeshi adults: evidence from a nation-wide survey","volume":"5","author":"Gupta RD","year":"2022","unstructured":"Gupta RD, Tamanna RJ, Akonde M, Biswas T, Chakraborty PA, Hossain MB. Prevalence and associated factors of metabolic syndrome among Bangladeshi adults: evidence from a nation-wide survey. Diabetes Epidemiol Manag. 2022, 5:100037. 10.1016\/j.deman.2021.100037","journal-title":"Diabetes Epidemiol Manag"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1093\/inthealth\/ihz093","article-title":"Metabolic syndrome and related risk factors among adults in the northern West Bank, a cross-sectional study","volume":"14","author":"Damiri B","year":"2022","unstructured":"Damiri B, Badran L, Safadi D, Sawalha A, Yasin Y, Sawalha M, Amir M. Metabolic syndrome and related risk factors among adults in the northern West Bank, a cross-sectional study. Int Health. 2022, 14:339-45. 10.1093\/inthealth\/ihz093","journal-title":"Int Health"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3390\/medicina59101747","article-title":"Particularities of urinary tract infections in diabetic patients: a concise review","volume":"59","author":"Confederat LG","year":"2023","unstructured":"Confederat LG, Condurache MI, Alexa RE, Dragostin OM. Particularities of urinary tract infections in diabetic patients: a concise review. Medicina (Kaunas). 2023, 59:10.3390\/medicina59101747","journal-title":"Medicina (Kaunas)"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott SD","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, et al.. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019, 380:347-57. 10.1056\/NEJMoa1812389","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s40801-023-00398-8","article-title":"Effectiveness of dapagliflozin as add-on to metformin with or without other oral antidiabetic drugs in type 2 diabetes mellitus: a multicentre, retrospective, real-world database study","volume":"11","author":"Sethi B","year":"2024","unstructured":"Sethi B, Sahay R, Tiwaskar M, et al.. Effectiveness of dapagliflozin as add-on to metformin with or without other oral antidiabetic drugs in type 2 diabetes mellitus: a multicentre, retrospective, real-world database study. Drugs Real World Outcomes. 2024, 11:81-90. 10.1007\/s40801-023-00398-8","journal-title":"Drugs Real World Outcomes"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1256548","article-title":"Comparative safety of different recommended doses of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis of randomized clinical trials","volume":"14","author":"Chen L","year":"2023","unstructured":"Chen L, Xue Q, Yan C, Tang B, Wang L, Zhang B, Zhao Q. Comparative safety of different recommended doses of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis of randomized clinical trials. Front Endocrinol (Lausanne). 2023, 14:1256548. 10.3389\/fendo.2023.1256548","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2025.111997","article-title":"Call to action for clinicians in the South-East Asian regions on primary prevention of diabetes in people with prediabetes- a consensus statement","volume":"221","author":"Ramachandran A","year":"2025","unstructured":"Ramachandran A, Nanditha A, Tuomilehto J, et al.. Call to action for clinicians in the South-East Asian regions on primary prevention of diabetes in people with prediabetes- a consensus statement. Diabetes Res Clin Pract. 2025, 221:111997. 10.1016\/j.diabres.2025.111997","journal-title":"Diabetes Res Clin Pract"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcjd.2024.08.002","article-title":"Pharmacologic glycemic management of type 2 diabetes in adults---2024 update","volume":"48","author":"Shah BR","year":"2024","unstructured":"Shah BR, Bajaj HS, Butalia S, et al.. Pharmacologic glycemic management of type 2 diabetes in adults---2024 update. Can J Diabetes. 2024, 48:415-24. 10.1016\/j.jcjd.2024.08.002","journal-title":"Can J Diabetes"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2024.103094","article-title":"Clinical practice guidelines for the management of type 2 Diabetes in South Asia: a systematic review","volume":"18","author":"Pervez A","year":"2024","unstructured":"Pervez A, Ahmer A, Mahmud O, et al.. Clinical practice guidelines for the management of type 2 Diabetes in South Asia: a systematic review. Diabetes Metab Syndr. 2024, 18:103094. 10.1016\/j.dsx.2024.103094","journal-title":"Diabetes Metab Syndr"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.20944\/preprints202410.1653.v2","article-title":"Association of SGLT2 inhibitors and urogenital infections in patients attending a tertiary care hospital: a prospective observational study (Preprint)","volume":"12","author":"Benoy A","year":"2024","unstructured":"Benoy A, Joseph M, Sabu JE, et al.. Association of SGLT2 inhibitors and urogenital infections in patients attending a tertiary care hospital: a prospective observational study (Preprint). Int J Adv Med. 2024, 12:50-6. 10.20944\/preprints202410.1653.v2","journal-title":"Int J Adv Med"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2023.110236","article-title":"Risk factors of dapagliflozin-associated diabetic ketosis\/ketoacidosis in patients with type 2 diabetes mellitus: A matched case-control study","volume":"196","author":"Zhao Z","year":"2023","unstructured":"Zhao Z, Zhao F, Zhang Y, et al.. Risk factors of dapagliflozin-associated diabetic ketosis\/ketoacidosis in patients with type 2 diabetes mellitus: A matched case-control study. Diabetes Res Clin Pract. 2023, 196:110236. 10.1016\/j.diabres.2023.110236","journal-title":"Diabetes Res Clin Pract"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.7326\/M19-0085","article-title":"Fournier gangrene associated with sodium-glucose cotransporter-2 inhibitors: a review of spontaneous postmarketing cases","volume":"170","author":"Bersoff-Matcha SJ","year":"2019","unstructured":"Bersoff-Matcha SJ, Chamberlain C, Cao C, Kortepeter C, Chong WH. Fournier gangrene associated with sodium-glucose cotransporter-2 inhibitors: a review of spontaneous postmarketing cases. Ann Intern Med. 2019, 170:764-9. 10.7326\/M19-0085","journal-title":"Ann Intern Med"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1089\/met.2022.0004","article-title":"Lipid profile changes associated with SGLT-2 inhibitors and GLP-1 agonists in diabetes and metabolic syndrome","volume":"20","author":"Premji R","year":"2022","unstructured":"Premji R, Nylen ES, Naser N, Gandhi S, Burman KD, Sen S. Lipid profile changes associated with SGLT-2 inhibitors and GLP-1 agonists in diabetes and metabolic syndrome. Metab Syndr Relat Disord. 2022, 20:321-8. 10.1089\/met.2022.0004","journal-title":"Metab Syndr Relat Disord"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.09.020","article-title":"2018 ACC expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a report of the American College of Cardiology task force on expert consensus","volume":"72","author":"Das SR","year":"2018","unstructured":"Das SR, Everett BM, Birtcher KK, et al.. 2018 ACC expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a report of the American College of Cardiology task force on expert consensus. J Am Coll Cardiol. 2018, 72:3200-23. 10.1016\/j.jacc.2018.09.020","journal-title":"J Am Coll Cardiol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13413","article-title":"Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study","volume":"20","author":"Fioretto P","year":"2018","unstructured":"Fioretto P, Del Prato S, Buse JB, et al.. Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study. Diabetes Obes Metab. 2018, 20:2532-40. 10.1111\/dom.13413","journal-title":"Diabetes Obes Metab"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-2419","article-title":"Efficacy of modern diabetes treatments DPP-4i, SGLT-2i, and GLP-1Ra in white and Asian patients with diabetes: a systematic review and meta-analysis of randomized controlled trials","volume":"43","author":"Gan S","year":"2020","unstructured":"Gan S, Dawed AY, Donnelly LA, Nair AT, Palmer CN, Mohan V, Pearson ER. Efficacy of modern diabetes treatments DPP-4i, SGLT-2i, and GLP-1Ra in white and Asian patients with diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Care. 2020, 43:1948-57. 10.2337\/dc19-2419","journal-title":"Diabetes Care"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/353988-effects-of-dapagliflozin-on-obese-patients-with-type-2-diabetes-a-prospective-observational-study-from-bangladesh","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T19:00:21Z","timestamp":1754334021000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/353988-effects-of-dapagliflozin-on-obese-patients-with-type-2-diabetes-a-prospective-observational-study-from-bangladesh"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,4]]},"references-count":33,"URL":"https:\/\/doi.org\/10.7759\/cureus.89360","relation":{},"ISSN":["2168-8184"],"issn-type":[{"type":"print","value":"2168-8184"}],"subject":[],"published":{"date-parts":[[2025,8,4]]}}}